Months post randomisation | 0 | 0 | 1 | 1 | 3 | 6 | 12 | 18 | Completed by |
Time point | Telephone screen | Baseline assessment | Mid-treatment (3 weeks) | Mid-treatment (5 weeks) | Primary end point | 6 months | 12 months | 18 months | |
Screening for eligibility | X | X | R | ||||||
SDQ & DAWBA (conducted post telephone screen and prior to baseline) | X | P & T | |||||||
YGTSS TTSS | X | X | X | X | X | R | |||
YGTSS impairment | X | X | X | X | X | R | |||
CAIDS-Q | X | P/R | |||||||
SCQ | X | P | |||||||
SNAP-IV | X | P | |||||||
Demographics | X | R | |||||||
PUTS | X | C | |||||||
PTQ | X | X | X | X | X | X | P | ||
CGAS | X | X | X | X | X | R | |||
CHU9D | X | X | X | X | X | P | |||
Modified CSRI (including school attendance) | X | X | X | X | X | P/R | |||
MFQ (self-report) | X | X | X | X | X | X | C | ||
SCAS (Self-report) | X | X | X | X | X | C | |||
C&A GTS-QOL | X | X | X | X | X | C | |||
Adverse effects/side effects | X | X | X | X | P/C | ||||
Concomitant interventions | X | X | X | X | X | P/R | |||
SDQ (P) | X | X | X | X | P | ||||
CGI-I | X | X | X | X | R | ||||
Treatment credibility | X | P/C | |||||||
Treatment satisfaction | X | P/C | |||||||
Need for further treatment | X | P/C | |||||||
Interview (process evaluation) | X |
C&A-GTS-QOL, Child and adolescent version of the Gilles de la Tourette Syndrome Quality of Life Scale; CAIDS-Q, Child and Adolescent Intellectual Disability Screening Questionnaire; CGAS, Children’s Global Assessment Scale; CGI-I, Clinical Global Impressions- Improvement; CHU9D, Child Health Utility 9D; CSRI, Client Service Receipt Inventory; DAWBA, Development and Wellbeing Assessment; MFQ, Mood and Feelings Questionnaire; P, parent; PTQ, Parent Tic Questionnaire; PUTS, Premonitory Urges for Tics Scale; R, researcher; SCAS, Spence Child Anxiety Scale; SCQ, Social Communication Questionnaire; SDQ, Strengths and Difficulties Questionnaire; SNAP-IV; Swanson, Nolan and Pelham Rating Scale; T, teacher; TTSS, Total Tic Severity Scale; YGTSS, Yale Global Tic Severity Scale.